• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Indivior Pharmaceuticals, Inc. - Common Stock (NQ:INDV)

    37.15 +1.72 (+4.85%)
    Streaming Delayed Price Updated: 10:20 AM EDT, Jun 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 339,526
    Open 35.80
    Bid (Size) 37.06 (200)
    Ask (Size) 37.22 (200)
    Prev. Close 35.43
    Today's Range 35.57 - 37.26
    52wk Range 12.36 - 41.00
    Shares Outstanding 128,000,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Indivior Pharmaceuticals (NASDAQ:INDV) Passes Minervini Trend Template and High Growth Momentum Screen ↗
    Via Chartmill
    News headline image
    What to Know About This Fund's $74.8 Million Indivior Sale ↗
    Indivior develops buprenorphine-based treatments for opioid dependence, serving markets in the US, UK, and worldwide. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +4.0%
    +4.0%
    1 Month
    -4.7%
    -4.7%
    3 Month
    +15.5%
    +15.5%
    6 Month
    +9.2%
    +9.2%
    1 Year
    +193.1%
    +193.1%

    More News

    Read More
    News headline image
    Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    What to Know About This Fund's $61.5 Million Exit From Ecovyst Amid a 75% Stock Rally ↗
    Via The Motley Fool
    Topics Regulatory Compliance Supply Chain
    Indivior Pharmaceuticals Inc (NASDAQ:INDV) Smashes Q1 Estimates and Lifts Full-Year Outlook as SUBLOCADE Sales Surge ↗
    Via Chartmill
    News headline image
    New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior to Participate in Upcoming Investor Conferences
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Why One Fund Made a $23 Million Bet on This Addiction-Treatment Stock Amid a Staggering Rally ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Indivior Pharmaceuticals Inc (NASDAQ:INDV) Shows High Growth Momentum and Technical Breakout Potential ↗
    Via Chartmill
    Indivior Pharmaceuticals Inc (NASDAQ:INDV) Surpasses Q4 2025 Estimates and Provides Strong 2026 Outlook ↗
    Via Chartmill
    News headline image
    Indivior Announces $175 Million Accelerated Share Repurchase
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior (INDV) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior Announces Proposed Convertible Senior Notes Offering
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Divisadero Dumps Stride Stock ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Indivior (INDV) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Indivior to Participate in Upcoming Investor Conferences
    From Indivior Pharmaceuticals Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Indivior Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Indivior Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Indivior Pharmaceuticals, Inc. - Common Stock trade on?
    Indivior Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Indivior Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Indivior Pharmaceuticals, Inc. - Common Stock is INDV on the Nasdaq Stock Market
    What is the current price of Indivior Pharmaceuticals, Inc. - Common Stock?
    The current price of Indivior Pharmaceuticals, Inc. - Common Stock is 37.15
    When was Indivior Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Indivior Pharmaceuticals, Inc. - Common Stock was at 06/04/26 10:20 AM ET
    What is the market capitalization of Indivior Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Indivior Pharmaceuticals, Inc. - Common Stock is 4.76B
    How many shares of Indivior Pharmaceuticals, Inc. - Common Stock are outstanding?
    Indivior Pharmaceuticals, Inc. - Common Stock has 5B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.